EFG Asset Management Americas Corp. Buys 6,106 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

EFG Asset Management Americas Corp. boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 56.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,992 shares of the biopharmaceutical company's stock after buying an additional 6,106 shares during the period. EFG Asset Management Americas Corp.'s holdings in Alnylam Pharmaceuticals were worth $4,129,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ALNY. V Square Quantitative Management LLC lifted its stake in Alnylam Pharmaceuticals by 21.9% in the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company's stock worth $81,000 after purchasing an additional 60 shares in the last quarter. Commerce Bank boosted its stake in shares of Alnylam Pharmaceuticals by 1.7% during the 4th quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company's stock valued at $896,000 after purchasing an additional 77 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 7.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company's stock valued at $262,000 after purchasing an additional 89 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Alnylam Pharmaceuticals by 54.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company's stock valued at $63,000 after acquiring an additional 91 shares during the period. Finally, Metis Global Partners LLC lifted its position in Alnylam Pharmaceuticals by 2.2% during the 4th quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company's stock valued at $839,000 after acquiring an additional 94 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Down 1.9 %

Shares of ALNY stock traded down $4.70 during trading hours on Friday, reaching $246.78. The company's stock had a trading volume of 682,407 shares, compared to its average volume of 903,035. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $287.55. The company has a market capitalization of $31.22 billion, a price-to-earnings ratio of -92.08 and a beta of 0.37. The firm's 50 day simple moving average is $257.35 and its 200-day simple moving average is $191.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The company's revenue for the quarter was up 107.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.21) earnings per share. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of research analyst reports. TD Cowen lifted their price target on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a "buy" rating in a research note on Tuesday, June 25th. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their target price for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. JPMorgan Chase & Co. upped their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a "neutral" rating in a research report on Monday, August 26th. Canaccord Genuity Group increased their price objective on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. Finally, UBS Group increased their price objective on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a "buy" rating in a research report on Friday, June 28th. Seven analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $279.14.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the company's stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the sale, the director now directly owns 136 shares of the company's stock, valued at $30,013.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director David E. I. Pyott sold 32,450 shares of the company's stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the transaction, the director now directly owns 136 shares in the company, valued at $30,013.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at $35,632. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 103,148 shares of company stock valued at $25,658,824. 1.50% of the stock is owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.